[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388254":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":40,"collaborators":7,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University Hospital, Grenoble","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Isolation of anti-Pseudomonas antibodies from type B lymphocytes","Blood sampling. Isolation of mononuclear cells from human peripheral blood by density gradient centrifugation. Identification of functional anti-Pseudomonas antibodies by ELISA and cellular infection assays.",[14],{"name":15,"affiliation":5,"role":16},"Yvan CASPAR, Dr","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","+33 4 76 76 54 79","ycaspar@chu-grenoble.fr",[23],{"facility":24,"status":25,"city":26,"state":7,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Chu Grenoble Alpes","RECRUITING","Grenoble","38043","France","FR",{"type":31,"coordinates":32},"Point",[33,34],5.71479,45.17869,{"lat":34,"lon":33},[37],{"name":15,"role":19,"phone":38,"phoneExt":7,"email":39},"+33 (0)4 76 76 63 12","YCaspar@chu-grenoble.fr",{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100388254","isolation-of-human-recombinant-therapeutic-monoclonal-anti-pseudomonas-antibodies-100388254",false,"NCT04335383","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies","Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies From B Lymphocytes of Patients Who Have Been Followed for Infection or Colonization With Pseudomonas Aeruginosa: a Prospective Monocentric Trial","ABAC-IBS","Inclusion Criteria:\n\n* Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)\n* Patient with weight ≥ 32kg.\n* With a follow-up visit at Grenoble University Hospital with a blood sampling for its care\n* Having given its written no objection to participate in the prospective phase of this project\n\nExclusion Criteria:\n\n* Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)","ALL","18 Years",{"count":53,"type":54},30,"ESTIMATED","OBSERVATIONAL","Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.\n\nThe aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.",[58,59],"Pseudomonas Aeruginosa","Multi-antibiotic Resistance",[61,62],"Pseudomonas aeruginosa","monoclonal antibody","2025-11-17",{"date":65,"type":66},"2025-11-20","ACTUAL",{"date":68,"type":66},"2020-10-05",{"date":70,"type":54},"2026-10",{"name":5,"class":6},1]